Andrew Han covers breaking news for GenomeWeb. He tracks companies in the molecular biology research and diagnostic markets.
The two papers published today in Science and Cell have implications for both forensics and genetic research.
The Virginia-based firm's genetic genealogy service for forensics played a central role in a recent arrest in a 30-year-old double homicide case.
There has been a proliferation of firms aiming to apply blockchain technology to genomics. While challenges remain, it may just provide the security needed for data sharing.
The firm is in the process of commercializing an open, optimizable, high-throughput library preparation instrument for single-cell transcriptome profiling.
By combining in vivo and in vitro proximity ligation technologies, highly accurate and contiguous genomes can help accelerate more traditional, genetic-marker based crop breeding.
Dubbed "Sherlock," the new technology has demonstrated potential in detecting viruses and bacteria as well as human SNPs and mutations in cell-free DNA.
Reinstating the CRISPR patent interference with the Broad Institute would allow UC to argue that Jennifer Doudna and Emmanuelle Charpentier invented it first.
The Harvard spinout is commercializing inDrop single-cell sequencing technology developed by Allon Klein.
The Merck KGaA subsidiary is launching the research-use only SMCxPRO later this year for protein detection using sandwich ELISAs paired with proprietary optical readout.
Specialized single-cell "cores" are popping up to help scientists get the most out of new technologies.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.